Personalized FLT3 Mutated Proliferative Disorder Treatment Platform

Publication ID: 24-11857546_0010_PTD

Published: October 28, 2025

Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Personalized FLT3 Mutated Proliferative Disorder Treatment Platform,” Published Technical Disclosure No. 24-11857546_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857546_0010_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,546.

Summary of the Inventive Concept

A next-generation treatment platform for FLT3 mutated proliferative disorders, integrating theranostics, personalized treatment regimens, and machine learning-driven treatment outcome predictions to revolutionize patient care.

Background and Problem Solved

The original patent disclosed the use of crenolanib for treating FLT3 mutated proliferative disorders. However, the current approach has limitations, including the need for manual dosage adjustments and the lack of personalized treatment strategies. The new inventive concept addresses these limitations by introducing a comprehensive platform that leverages advanced diagnostics, machine learning, and precision medicine to provide tailored treatments for individual patients.

Detailed Description of the Inventive Concept

The inventive concept comprises a theranostic module that identifies a patient's FLT3 mutation profile, a personalized treatment regimen generator that recommends customized crenolanib-based therapy, and a machine learning-driven treatment outcome prediction system. The platform dynamically adjusts the dosage of crenolanib based on the patient's FLT3 mutation profile over time, ensuring optimal treatment outcomes. Additionally, the platform incorporates a kit for treating FLT3 mutated proliferative disorders, including a container of crenolanib, a companion diagnostic, and instructions for use that incorporate machine learning algorithms.

Novelty and Inventive Step

The new inventive concept introduces a paradigm shift in the treatment of FLT3 mutated proliferative disorders by integrating advanced diagnostics, machine learning, and precision medicine. The novel combination of theranostics, personalized treatment regimens, and dynamic dosage adjustment provides a significant improvement over the current approach, making the original patent's concept obsolete.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the integration of additional therapeutic agents, the use of different machine learning algorithms, or the incorporation of real-time patient monitoring data to further optimize treatment outcomes.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the oncology market, particularly in the treatment of FLT3 mutated proliferative disorders. The platform's ability to provide personalized treatment strategies and improve treatment outcomes could lead to increased adoption and market share, with potential applications in other disease areas as well.

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Oncology, pharmaceutical therapeutics, and precision medicine with a focus on targeted cancer treatments involving tyrosine kinase inhibitors and personalized diagnostic approaches

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced degrees in pharmacology, oncology, or biomedical engineering, possessing expertise in molecular diagnostics, cancer treatment strategies, and computational biology techniques

Obviousness Rationale

A PHOSITA would recognize that the PTD's integration of machine learning, personalized treatment regimens, and dynamic dosage adjustment represents a natural progression of the source patent's foundational work on crenolanib treatment for FLT3 mutated disorders. The technical variations demonstrate predictable extensions of existing precision medicine approaches by applying known computational and diagnostic techniques to the established therapeutic framework. The systematic approach of monitoring mutation profiles and adjusting treatment accordingly would be an expected innovation for a skilled practitioner seeking to optimize patient outcomes.

Obvious Combinations & Variations

Source Patent Element

Method for treating FLT3 mutated hematological malignancies using crenolanib

PTD Variation

Theranostic module for identifying patient-specific FLT3 mutation profiles and dynamically adjusting treatment

Obviousness Reasoning

Predictable application of personalized medicine techniques to existing targeted cancer treatment methodology, representing a logical refinement of precision diagnostic approaches

Source Patent Element

Dosage ranges for crenolanib treatment (50-500 mg per day)

PTD Variation

Machine learning-driven dynamic dosage adjustment based on real-time mutation profile monitoring

Obviousness Reasoning

Known technique of adaptive dosing combined with computational predictive modeling, representing an obvious optimization strategy for targeted therapeutics

Source Patent Element

Treatment of hematological malignancies with tyrosine kinase inhibitors

PTD Variation

Companion diagnostic kit integrating machine learning algorithms for treatment outcome prediction

Obviousness Reasoning

Predictable extension of existing diagnostic approaches by incorporating computational predictive techniques commonly used in precision medicine

Source Patent Element

FLT3 mutation identification as basis for treatment selection

PTD Variation

Genomic data analysis to identify novel therapeutic targets associated with treatment resistance

Obviousness Reasoning

Standard scientific approach of expanding understanding through systematic genomic investigation, representing an expected progression in targeted cancer research

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857546 and the published technical disclosure, a person of ordinary skill in the art would find the claimed variations obvious, as they represent predictable applications of known precision medicine techniques to established crenolanib treatment methodologies. The systematic integration of machine learning, dynamic dosage adjustment, and personalized diagnostic approaches constitutes an obvious extension of existing targeted therapeutic strategies, rendering potential patent claims obvious and unpatentable under 35 U.S.C. Section 103.

Original Patent Information

Patent Number	US 11,857,546
Title	Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment
Assignee(s)	Arog Pharmaceuticals, Inc.